VistaGen Therapeutics is dedicated to developing and commercializing novel product candidates for patients with central nervous system (CNS) conditions. Their lead candidate, AV-101, is an orally available prodrug currently in Phase 2 development for Major Depressive Disorder (MDD). VistaGen also has three other clinical-stage CNS drug candidates: PH94B, PH10, and AV-101. PH94B is being investigated as a potential treatment for social anxiety disorder (SAD) and has received Fast Track designation from the FDA. PH10 is being developed as a self-administered treatment for major depressive disorder (MDD). AV-101, a prodrug of 7-Cl-KYNA, has shown promise in preclinical studies for multiple CNS indications and has received Fast Track designation for both MDD and neuropathic pain. VistaGen's pipeline demonstrates differentiated mechanisms of action, exceptional safety profiles, and therapeutic potential in various CNS markets.